down arrow

Fujian Cosunter Pharmaceutical Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100001YZ0
CNY
91.28
0.66 (0.73%)

Dec 05

SHE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Fujian Cosunter Pharmaceutical Co., Ltd.
Why is Fujian Cosunter Pharmaceutical Co., Ltd. ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Net Sales has grown by an annual rate of 2.85% and Operating profit at -383.94% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2
Negative results in Mar 25
  • DEBT-EQUITY RATIO (HY) Highest at 98.46 %
  • INVENTORY TURNOVER RATIO(HY) Lowest at 1.47%
  • DEBTORS TURNOVER RATIO(HY) Lowest at 5.75%
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 240.83%, its profits have risen by 13.8%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Fujian Cosunter Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Fujian Cosunter Pharmaceutical Co., Ltd.
240.6%
5.67
96.78%
China Shanghai Composite
15.19%
1.01
15.10%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
2.85%
EBIT Growth (5y)
-383.94%
EBIT to Interest (avg)
-7.71
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.98
Sales to Capital Employed (avg)
0.42
Tax Ratio
6.48%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.56%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
49.45
EV to EBIT
-79.69
EV to EBITDA
-173.12
EV to Capital Employed
23.47
EV to Sales
35.06
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-29.45%
ROE (Latest)
-70.63%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 39.05 MM

NET PROFIT(HY)

Higher at CNY -114.15 MM

RAW MATERIAL COST(Y)

Fallen by -29.38% (YoY

-12What is not working for the Company
DEBT-EQUITY RATIO (HY)

Highest at 98.46 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.47%

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.75%

NET SALES(Q)

Lowest at CNY 95.45 MM

Here's what is working for Fujian Cosunter Pharmaceutical Co., Ltd.
Operating Cash Flow
Highest at CNY 39.05 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Profit
Higher at CNY -114.15 MM
than preceding 12 month period ended Mar 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Raw Material Cost
Fallen by -29.38% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Fujian Cosunter Pharmaceutical Co., Ltd.
Debt-Equity Ratio
Highest at 98.46 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Net Sales
Lowest at CNY 95.45 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)

Net Sales
At CNY 95.45 MM has Fallen at -11.62%
over average net sales of the previous four periods of CNY 108.01 MM
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)

Inventory Turnover Ratio
Lowest at 1.47%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 5.75%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."